Enzyme inhibition competitive/reversible

Following concurrent administration of two drugs, especially when they are metabolized by the same enzyme in the liver or small intestine, the metabolism of one or both drugs can be inhibited, which may lead to elevated plasma concentrations of the dtug(s), and increased pharmacological effects. The types of enzyme inhibition include reversible inhibition, such as competitive or non-competitive inhibition, and irreversible inhibition, such as mechanism-based inhibition. The clinically important examples of drug interactions involving the inhibition of metabolic enzymes are listed in Table 1 [1,4]. 

Among all the interactions-based PBTK models published to date, reversible metabolic inhibition is by far the most frequently encountered type of interaction. There are 3 types of reversible enzyme inhibition competitive, noncompetitive, and uncompetitive (Table 2.2), and examples of all are listed in Table 2.3. A large number of examples of such metabolic inhibition in humans and laboratory animals are available for specific CYP enzymes and therapeutic drugs (Dome et al. 2007b). 

Since enzyme inhibition involves reversible mechanisms, CLi , (ij may vary with regard to the type and concentration of inhibitor. The concentrations of an inhibitor (or drug) that are relevant to clinical application can be approached for the prediction in the in vivo situation. In practice, a ratio in AUC, hepatic clearance (CLhept), plasma concentration at steady state (Css), or intrinsic clearance (CLjnt) caused by metabolism-based DDIs is commonly used to assess the degree of metabolism inhibition in vivo (Eq. 16.7). If a drug is eliminated due to both metabolism and renal excretion, the fraction of the drug metabolized by the inhibited enzyme (fj ) should be introduced to the prediction. With inclusion of fj, the ratio change in AUC in the presence and absence of an inhibitor can be expressed for competitive and noncompetitive (Eq. 16.8). 

Probably all adenylyl cyclases are inhibited competitively by substrate analogs, which bind at the site and to the enzyme configuration with which cation-ATP binds (cf Fig. 4). One of the best competitive inhibitors is (3-L-2, 3 -dideoxy adenosine-5 -triphosphate ( 3-L-2, 3 -dd-5 -ATP Table 4) [4], which allowed the identification of the two metal sites within the catalytic active site (cf Fig. 4) [3]. This ligand has also been labeled with 32P in the (3-phosphate and is a useful ligand for reversible, binding displacement assays of adenylyl cyclases [4]. The two inhibitors, 2, 5 -dd-3 -ATP and 3-L-2, 3 -dd-5 -ATP, are comparably potent... 

Figure 3.2 Cartoon representations of the three major forms of reversible inhibitor interactions with enzymes (A) competitive inhibition (B) noncompetitive inhibition (C) uncompetitive inhibition. Source-. From Copeland (2000).

In this chapter we described the thermodynamics of enzyme-inhibitor interactions and defined three potential modes of reversible binding of inhibitors to enzyme molecules. Competitive inhibitors bind to the free enzyme form in direct competition with substrate molecules. Noncompetitive inhibitors bind to both the free enzyme and to the ES complex or subsequent enzyme forms that are populated during catalysis. Uncompetitive inhibitors bind exclusively to the ES complex or to subsequent enzyme forms. We saw that one can distinguish among these inhibition modes by their effects on the apparent values of the steady state kinetic parameters Umax, Km, and VmdX/KM. We further saw that for bisubstrate reactions, the inhibition modality depends on the reaction mechanism used by the enzyme. Finally, we described how one may use the dissociation constant for inhibition (Kh o.K or both) to best evaluate the relative affinity of different inhibitors for ones target enzyme, and thus drive compound optimization through medicinal chemistry efforts. 

The mechanisms which underlie enzyme inhibition are described more fully in Chapter 3. Suffice to say here that reversible inhibitors which block the active site are called competitive whilst those which prevent release of the product of the reaction are non-competitive. By preventing the true substrate accessing the active site, competitive inhibitors increase Km (designated by or K PParent). A non-competitive inhibitor decreases V mprime symbol ( ) here to imply physiological as it does for energy change. 

Most enzyme inhibitors act reversibly—i. e., they do not cause any permanent changes in the enzyme. However, there are also irreversible inhibitors that permanently modify the target enzyme. The mechanism of action of an inhibitor—its inhibition type—can be determined by comparing the kinetics (see p.92) of the inhibited and uninhibited reactions (B). This makes it possible to distinguish competitive inhibitors (left) from noncompetitive inhibitors (right), for example. Allosteric inhibition is particularly important for metabolic regulation (see below). 

Reversible Inhibition One common type of reversible inhibition is called competitive (Fig. 6-15a). A competitive inhibitor competes with the substrate for the active site of an enzyme. While the inhibitor (I) occupies the active site it prevents binding of the substrate to the enzyme. Many competitive inhibitors are compounds that resemble the substrate and combine with the enzyme to form an El complex, but without leading to catalysis. Even fleeting combinations of this type will reduce the efficiency of the enzyme. By taking into account the molecular geometry of inhibitors that resemble the substrate, we can reach conclusions about which parts of the normal substrate bind to the enzyme. Competitive inhibition can be analyzed quantitatively by steady-state kinetics. In the presence of a competitive inhibitor, the Michaelis-Menten equation (Eqn 6-9) becomes... 

Reversible inhibition of an enzyme is competitive, uncompetitive, or mixed. Competitive inhibitors compete with substrate by binding reversibly to the active site, but they are not transformed by the enzyme. Uncompetitive inhibitors bind only to the ES complex, at a site distinct from the active site. Mixed inhibitors bind to either E or ES, again at a site distinct from the active site. In irreversible inhibition an inhibitor binds permanently to an active site by forming a covalent bond or a veiy stable noncovalent interaction. 

There are two reports that hydroxamic acid inhibition is reversible 59,90) and one that inhibition is irreversible (91). The inhibition appears to be competitive. The rather extensive screening of 36 hydroxamic acids was accomplished with sword bean urease (90), but Proteus urease (92) and jack bean urease (59) also have been found to be inhibited by these specific inhibitors. Using tritium-labeled caprylohydroxamic acid and sword bean urease, Kobashi et al. (94) have shown the formation of an inactive complex containing two moles of inhibitor per mole of enzyme. 

The ability of Pi to inhibit competitively with respect to phosphate substrates (104), while not being incorporated into protein-bound phos-phohistidine (156) or participating in glucose-6-P synthesis by reversal of the hydrolytic reaction (30), also is explainable in terms of these mechanistic concepts. As shown in (XX), Fig. 8, binding of the P to enzyme-bound metal ion, without further formation of a P-N bond with imidazole N, would explain all of these experimental observations. 

Reversible inhibition occurs rapidly in a system which is near its equilibrium point and its extent is dependent on the concentration of enzyme, inhibitor and substrate. It remains constant over the period when the initial reaction velocity studies are performed. In contrast, irreversible inhibition may increase with time. In simple single-substrate enzyme-catalysed reactions there are three main types of inhibition patterns involving reactions following the Michaelis-Menten equation competitive, uncompetitive and non-competitive inhibition. Competitive inhibition occurs when the inhibitor directly competes with the substrate in forming the enzyme complex. Uncompetitive inhibition involves the interaction of the inhibitor with only the enzyme-substrate complex, while non-competitive inhibition occurs when the inhibitor binds to either the enzyme or the enzyme-substrate complex without affecting the binding of the substrate. The kinetic modifications of the Michaelis-Menten equation associated with the various types of inhibition are shown below. The derivation of these equations is shown in Appendix S.S. 

The title compound, 2-(8-dimethylaminooctylthio)-6-isopropyl-3-pirydyl-2-thienyl ketone (222), a potent competitive reversible inhibitor of the enzyme PEP (prolyl endopeptidase which cleaves a variety of oligopeptides in brain and peripheral tissues217), has been synthesized218 by ["CJalkylation of the iV-desmethyl precursor 223 (equation 117). 222 crosses the BBB and inhibits brain PEP in rodents219. It is used in the study of biodistribution and activity of brain proteases by PET to evaluate the roles... 

The catalytic rate of an enzyme can be lowered by inhibitor molecules. Many inhibitors exist, including normal body metabolites, foreign drugs and toxins. Enzyme inhibition can be of two main types irreversible or reversible. Reversible inhibition can be subdivided into competitive and noncompetitive. 

Enzyme inhibition Many types of molecule exist which are capable of interfering with the activity of an individual enzyme. Any molecule which acts directly on an enzyme to lower its catalytic rate is called an inhibitor. Some enzyme inhibitors are normal body metabolites that inhibit a particular enzyme as part of the normal metabolic control of a pathway. Other inhibitors may be foreign substances, such as drugs or toxins, where the effect of enzyme inhibition could be either therapeutic or, at the other extreme, lethal. Enzyme inhibition may be of two main types irreversible or reversible, with reversible inhibition itself being subdivided into competitive and noncompetitive inhibition. Reversible inhibition can be overcome by removing the inhibitor from the enzyme, for example by dialysis (see Topic B6), but this is not possible for irreversible inhibition, by definition. 

Substances which interfere with the specific binding of the substrate to the prosthetic group are specific inhibitors, and differ significantly from agents, which cause nonspecific denaturation of an enzyme (or any protein). Two basic types of inhibitions are recognized competitive inhibition and noncompetitive inhibition. Competitive inhibition is the result of a reversible formation of an enzyme inhibitor complex (El) ... 

For competitive, reversible enzyme inhibition, the lowest measurable IC50 value is half of the enzyme concentration used in the assay (Cheng and Prusoff, 1973). From a practical view, kcJKM values of 104 M 1 s 1 and above are desirable for inhibitor profiling assays. With an enzyme-substrate pair characterized by a kcJKM value of 104 M 1 s, an assay can usually be run with a protease concentration in the single-digit nanomolar range in an automated setting. 

Most therapeutic drugs are reversible competitive inhibitors, which bind at the catalytic (active site) of the enzyme. Competitive inhibitors are especially attractive as clinical modulators of enzyme activity because they offer two routes for the reversal of enzyme inhibition, by decreasing the concentration of inhibitor or by raising the concentration of substrate. 

Competitive The catalytic site (usually), competing with substrate for binding in a dynamic equilibrium-like process. Inhibition is reversible by increasing substrate concentration. Vmax is unchanged Km is increased (the presence of inhibitor effectively decreases the affinity of the enzyme for its substrate). 

The effect of NMMA is attributable to its prevention of NO formation by NOS and its reversal by excess substrate (l-arginine) is a classic example of competitive enzyme inhibition (Figure 2). 

This article describes various approaches to inhibition of enzyme catalysis. Reversible inhibition includes competitive, uncompetitive, mixed inhibition, noncompetitive inhibition, transition state, and slow tight-binding inhibition. Irreversible inhibition approaches include affinity labeling and mechanism-based enzyme inhibition. The kinetics of the various inhibition approaches are summarized, and examples of each type of Inhibition are presented. 

The most common type of reversible inhibition is when the inhibitor binds to the free enzyme in the substrate binding site (called the active site), which is known as competitive reversible inhibition. Competitive inhibition prevents the substrate from binding because of a competition between the substrate and inhibitor for binding to the active site (Scheme 1). Particularly in medicinal chemistry, another common expression of inhibition, in addition to the Ki, is the /C50 value, the concentration of an inhibitor that results in 50% inhibition of the enzyme in the presence of a specific concentration of substrate. The IC50 and Ki values for a competitive reversible inhibitor are roughly interconverted by the following expression (Eq. 1) (1-3)... 

Irreversible enzyme inhibition, also cahed enzyme inactivation (or active-site directed ineversible inhibition, because it is generally competitive with substrate), occurs when a compound blocks the enzyme activity for an extended period of time, generally via covalent bond formation. Therefore, even though some slow tight-binding inhibitors functionahy block the enzyme activity irreversibly, they are stih considered reversible... 

All of the azides investigated were time-dependent inhibitors at millimolar concentrations and the inhibition was reversible in each case, with hepatic glutathione 5-transferase proving the most sensitive enzyme. Inhibitor potency appears to depend upon the substrate employed, -heptyl and allyl azides (60) and (62) being the most potent with NBC, and -butyl and -hexyl azide (57) and (59) when DNCB was included in the assay. Kinetic studies, where the GSH and DNCB concentrations were independently varied, indicated that compounds (61),(63) and (64) were noncompetitive inhibitors, while allyl azide (62) and the n-alkyl azides (56)-(60) inhibited the enzyme in a competitive manner. From these observations, the authors speculate that, in a process reminiscent of that known to occur with alkyl and aryl halides, glutathione 5-transferase may catalyse the conjugation of azides with GSH in vivo. 

---